Figure 3
Figure 3. Characterization of Bdkrb2−/− platelets. (A) Wild-type and Bdkrb2−/− platelet fluorescence with the NO marker DAF-FM (n = 4 samples in each group). The white line is a 20-μm marker. (B) cGMP (left) (n = 6 in each group) and cAMP (right) (n = 12 in each group) in resting wild-type or Bdkrb2−/− platelets. (C) Platelet spreading on collagen by phalloidin staining of cytoskeletal actin from wild-type, Bdkrb2−/− alone, or Bdkrb2−/− treated in vivo with combined L-NAME and nimesulide (L&N) or A-779. (D) The quantification of the data in (C), n ≥ 13 random fields in each group from 3 independent experiments on multiple days. (E) Bdkrb2+/+ or Bdkrb2−/− platelet spreading on the peptide GFOGER. (F) Quantification of the data from (E) (n ≥ 12 random fields from 2 independent experiments). The white line in (C) and (E) is a 5-μm marker. A.U., arbitrary units.

Characterization of Bdkrb2−/− platelets. (A) Wild-type and Bdkrb2−/− platelet fluorescence with the NO marker DAF-FM (n = 4 samples in each group). The white line is a 20-μm marker. (B) cGMP (left) (n = 6 in each group) and cAMP (right) (n = 12 in each group) in resting wild-type or Bdkrb2−/− platelets. (C) Platelet spreading on collagen by phalloidin staining of cytoskeletal actin from wild-type, Bdkrb2−/− alone, or Bdkrb2−/− treated in vivo with combined L-NAME and nimesulide (L&N) or A-779. (D) The quantification of the data in (C), n ≥ 13 random fields in each group from 3 independent experiments on multiple days. (E) Bdkrb2+/+ or Bdkrb2−/− platelet spreading on the peptide GFOGER. (F) Quantification of the data from (E) (n ≥ 12 random fields from 2 independent experiments). The white line in (C) and (E) is a 5-μm marker. A.U., arbitrary units.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal